Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

Henriette Huber, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Can Zhang, Eugen Tausch, Christof Schneider, Johannes Bloehdorn, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Durig, Sebastian Böttcher, Carsten Utoft Niemann, Michael Kneba, Anna Maria Fink, Kirsten Fischer, Hartmut DöhnerMichael Hallek, Barbara Eichhorst, Stephan Stilgenbauer

Fingeraftryk

Dyk ned i forskningsemnerne om 'Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia'. Sammen danner de et unikt fingeraftryk.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science